Wedelolactone
Catalog No: CFN98857
Wedelolactone is a potent Î2-arrestin-biased G protein-coupled receptor-35 (GPR35) agonist, GPR35 has been shown to be a target of the asthma drugs cromolyn disodium and nedocromil sodium. Wedelolactone has anti-inflammatory, growth inhibitory, anti-cancer, anti-fibrotic, and pro-apoptotic effects. Wedelolactone stimulates ER genomic and non-genomic signalling pathways; it can significantly inhibit the activation of LX-2 cells, the underlying mechanisms of which included inducing Bcl-2 family involved apoptosis, up-regulating phosphorylated status of ERK and JNK expressions, and inhibiting NF-κB mediated activity.
Kirenol
Catalog No: CFN98867
Kirenol possesses anti-bacteria, immunosuppression, anti-obesity, anti-oxidant, anti-inflammatory, anti-allergic, and anti-arthritic activities. Kirenol has significant potential for its discovery as a new lead compound for management of topical pain and inflammation; it can upregulate nuclear Annexin-1 which interacts with NF-κB to attenuate synovial inflammation of collagen-induced arthritis in rats. Kirenol can attenuate experimental autoimmune encephalomyelitis by inhibiting differentiation of Th1 and th17 cells and inducing apoptosis of effector T cells. Kirenol activates the BMP and Wnt/β-catenin signaling pathways.
Galangin
Catalog No: CFN98918
Galangin is an agonist/antagonist of the arylhydrocarbon receptor, and also shows inhibition of CYP1A1 activity. Galangin has anti-proliferation, anti-metastatic, anti-inflammatory, vasorelaxant, antiviral, anti-allergic inflammatory,anti-obesity effects; it may be a potential candidate for the treatment of vitiligo. Galangin can inhibit Topo I activity and reduce the unwinding rate of single stranded DNNA in tumor cells, which plays an important role in induction of A549 and H46 cell apoptosis. Galangin shows an inhibitory effect on acetylcholinesterase (AChE) activity with the IC(50) of 120 microM;
it also inhibits ERK, NF-κB-p65 and proinflammatory gene expression.
